Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Totenko, 2% Increase in Ordinary Profit for The Current Fiscal Year
8181 Totenko Co., Ltd. 【J-GAAP】
Earnings ReportTotenko Co., Ltd. <8181> [TSE Std] announced its financial results after the market closed on April 14th (15:30). The ordinary profit (non-consolidated) for the fiscal year ending February 2025 increased 18.5% from the previous period to 461 million yen. In the fiscal year ending February 2026, the profit is expected to grow by 2.0% to 470 million yen. This will be the fifth consecutive term of revenue growth.
In the most recent three-month period, from December to February (4Q), the ordinary profit amounted to 164 million yen, an increase of 0.6% compared to the same period last year. However, the operating profit margin decreased from 13.1% in the same period last year to 12.6%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2023 | 3,704 | -606 | -467 | -828 | -322.5 | 0 | Apr 17, 2023 | J-GAAP |
Feb, 2024 | 4,679 | 424 | 389 | -134 | -52.5 | 0 | Apr 15, 2024 | J-GAAP |
Feb, 2025 | 4,710 | 490 | 461 | 430 | 167.5 | 15 | Apr 14, 2025 | J-GAAP |
YoY | +0.7% | +15.6% | +18.5% | - | - |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2025 Guidance | 4,600 | 470 | 450 | 430 | 167.4 | 15 | Mar 17, 2025 | J-GAAP |
Feb, 2025 Results | 4,710 | 490 | 461 | 430 | 167.5 | 15 | Apr 14, 2025 | J-GAAP |
Revision Rate | +2.4% | +4.3% | +2.4% | 0.0% | +0.0% |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar - Aug, 2024 | 2,097 | 155 | 144 | 127 | 49.7 | 0 | Oct 10, 2024 | J-GAAP |
Mar - Aug, 2025 Guidance | 2,000 | 140 | 120 | 105 | 40.9 | 0 | Apr 14, 2025 | J-GAAP |
YoY | -4.6% | -9.7% | -16.7% | -17.3% | -17.7% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Feb, 2024 | 4,679 | 424 | 389 | -134 | -52.5 | 0 | Apr 15, 2024 | J-GAAP |
Feb, 2025 | 4,710 | 490 | 461 | 430 | 167.5 | 15 | Apr 14, 2025 | J-GAAP |
Feb, 2026 Guidance | 4,800 | 510 | 470 | 440 | 171.3 | 15 | Apr 14, 2025 | J-GAAP |
YoY | +1.9% | +4.1% | +2.0% | +2.3% | +2.3% |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec - Feb, 2023 | 1,295 | 170 | 163 | 159 | 62.3 | 13.1 | Apr 15, 2024 | J-GAAP |
Mar - May, 2024 | 1,143 | 139 | 132 | 120 | 46.9 | 12.2 | Jul 11, 2024 | J-GAAP |
Jun - Aug, 2024 | 954 | 16 | 12 | 7 | 2.7 | 1.7 | Oct 10, 2024 | J-GAAP |
Sep - Nov, 2024 | 1,240 | 162 | 153 | 150 | 58.6 | 13.1 | Jan 10, 2025 | J-GAAP |
Dec - Feb, 2024 | 1,373 | 173 | 164 | 153 | 59.6 | 12.6 | Apr 14, 2025 | J-GAAP |
YoY | +6.0% | +1.8% | +0.6% | -3.8% | -4.3% |
Related Articles
Copa Corp, Net Income/Loss Unexpectedly Turn to Loss for Last Fiscal Year, The Current Fiscal Year's Net Income to Narrow
STUDIO ALICE, 6% Decrease in Ordinary Profit for The Current Fiscal Year
COSMOS Pharma, Jun-Feb (Cumulative 3Q) Ordinary Profit Increases by 30%, Dec-Feb Ordinary Profit Increases by 40%
FP Partner, Dec-Feb (1Q) Ordinary Profit Decreases by 42%
DIP, 10% Decrease in Ordinary Profit for The Current Fiscal Year
Asterisk, The Current Fiscal Year Ordinary Profit Revised Downward by 82%
Maruto Sangyo, 15% Increase in Ordinary Profit for The Current Fiscal Year
VALUE CREATION, 50% Increase in Ordinary Profit, Record High for The First Time in Two Years, Dividend Raised by 0.5 yen
Daito Pharma, The Current Fiscal Year Ordinary Profit Revised Downward by 26%
KAWAKAMI PAINT, Dec-Feb (1Q) Ordinary Profit Turns to Loss